CA
AVDL

Cetera Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Cetera Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.55M Buy
92,017
+7,531
+9% +$112K 0.01% 939
2023
Q4 		$1.19M Sell
84,486
-3,385
-4% -$39.8K 0.02% 701
2023
Q3 		$905K Buy
+87,871
New +$1.18M 0.01% 763

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cetera Advisors's AVDL Position: Q1 2024 in Review

Cetera Advisors increased its Avadel Pharmaceuticals (AVDL) stake by 8.9% in Q1 2024, buying an estimated $112K and bringing the position to 92,017 shares worth $1.55M. The position accounts for 0.01% of the portfolio, ranked #939.

Cetera Advisors first reported a position in AVDL in Q3 2023 and has held it in 3 quarters since. 127 funds tracked by Wall St. Rank hold AVDL as of Q1 2024.

  • Cetera Advisors held 92,017 shares of Avadel Pharmaceuticals worth $1.55M as of Q1 2024.
  • Cetera Advisors bought 7,531 Avadel Pharmaceuticals shares in Q1 2024, an estimated $112K.
  • Avadel Pharmaceuticals made up 0.01% of Cetera Advisors's portfolio in Q1 2024, its #939 holding.
  • Cetera Advisors first reported a position in Avadel Pharmaceuticals in Q3 2023 and has held it in 3 quarters since.
  • 127 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.